MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Cook Rising to the Top

After having its best month on record in October, Cook Group's endovascular unit appears to be a force to be reckoned with. Barry Thomas, director of the strategic business unit, presented promising data during its media and analyst briefing last week in New York. So far, 2006 global sales in the endovascular unit are up more than 22%, with strong growth coming from markets in Asia and Latin America.

Cook's abdominal aortic aneurysm (AAA) stent graft, Zenith, is a strong competitor in the endovascular sector and was recently launched in Japan (it's also is the first and only such device there). And out of the 6200 AAA stent grafts implanted in the United States in the third quarter, the Zenith endograft came in second with 37% of the market, behind Gore's graft by a mere 1%. However, during the same quarter in Europe, Zenith was at the top with 47% of the market and a 15% lead. Cook's endovascular unit has also expanded in Japan, Taiwan, and South America, and is positioned in what Thomas labeled the "emerging" markets of China, India, and Korea. The division is also keeping endovascular disorders such as disease in the ascending aorta and thoraco-abdominal disease on its radar screen for future device development.

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish